GlobeNewswire

Quark Acquires Docurated: Enterprise Sales Asset Management Meets Content Automation

Dela

Enterprise Sales Enablement Solution Integrates with End-to-End Platform for Content Automation to Create, Manage, Predict, and Deliver Sales-Critical Content

Denver, CO, Dec. 06, 2017 (GLOBE NEWSWIRE) -- Quark Software announced today it has acquired Docurated, the creators of enterprise sales enablement solutions. Since its inception in 2012, Docurated has been recognized as a pioneer in SaaS-based enterprise sales and marketing software. Quark will integrate Docurated with Quark's content automation platform to enable sales teams to easily identify and deliver meaningful content to customer prospects.

Quark's content automation platform is used by the world's most recognized brands to streamline and optimize the lifecycle of business-critical content - from creation and management to publishing and delivery. Now with Docurated, Quark will solve the content challenges that sales and marketing teams face universally. With processes driven by automation and artificial intelligence (AI), Quark and Docurated will increase the agility and responsiveness of global sales teams.

Cheri Keith, Senior Research Analyst at SiriusDecisions, said, "Content and marketing leaders have focused on increasing the quality of content being produced and efficiency of their content engines, but that's not enough. Now they must also focus on the delivery of this content to sales teams. To empower sellers and buyers with the most relevant content, marketers already rely on tried and true practices, like taxonomies and metadata tagging, but they also need to look forward at new technologies. While still in its early days, b-to-b leaders are beginning to understand the power of artificial intelligence capabilities to augment their processes, including content creation and activation."

"In just months of introducing our new investors we have made our first acquisition to further fuel Quark's growth," said Ray Schiavone, Quark President and CEO. "We believe Docurated has the best technology and user experience for sales professionals who must deliver the right content to the right prospects at the right time. Combined with Quark's existing content automation platform, we believe there is no better end-to-end platform for the sales and marketing content lifecycle."

As a part of the acquisition, Docurated customers will continue to work directly with the Docurated team, while benefiting from Quark's expertise in broader content management and content automation solutions. 

"When we started Docurated five years ago, we wanted to bring greater intelligence to how content is created and distributed within sales and marketing," said Alex Gorbansky, CEO and Founder of Docurated. "I believe our incredible roster of clients speaks to our success in achieving this goal. As part of Quark, we're excited to be able to extend the benefits of Quark's content automation solutions, deliver even more personalized content, and transform the early stages of the content lifecycle."

About Quark Software Inc.
Quark Software Inc., a Parallax Capital Partners portfolio company, develops a content automation platform that helps large organizations streamline the creation, management, publishing and delivery of business-critical content. The solutions automate the process with reusable Smart Content components that can be dynamically assembled and delivered with precision in any format and to any channel - web, tablet, mobile, print, and more. As a result, leaders in industries such as finance, manufacturing, energy, and government can reduce costs, save time, improve consistency and make their content brilliant.

About Parallax Capital Partners
Parallax Capital Partners, LLC is a private equity firm focused on acquiring and operating application software and related services companies. Since 1999, Parallax has acquired over 20 companies. For more information, visit www.parallaxcap.com.

Quark and the Quark logo are trademarks or registered trademarks of Quark Software Inc. and its affiliates in the U.S. and/or other countries.

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/3cf3f8ba-4ce0-4e2d-9086-2fc3f54b844a

Sarah Rector
Quark Software Inc. 
303-894-3753
srector@quark.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Quark Software Inc. via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Stillfront: Simutronics återtar förläggartjänster10.12.2018 14:11Pressmeddelande

PRESSMEDDELANDE 2018-12-10 Simutronics återtar förläggartjänster för SIEGE: Titan Wars globalt med undantag för Kina Simutronics, en studio inom Stillfront Group, har avslutat ett medförläggaravtal avseende mobilspelet SIEGE: Titan Wars med den New York-baserade förläggarpartnern Tilting Point. Enligt ett nytt avtal kommer Tilting Point fortsatt att tillhandahålla förläggartjänster och marknadsföring av spelet i Kina men på global nivå kommer Simutronics att ansvara för förläggartjänster och marknadsföring av spelet från gruppen. Simutronics är en ledande utvecklare av rollspel och mobila spel som till exempel DragonRealms, GemStone IV och Lara Croft Relic Run, den sistnämnda med mer än 23 miljoner nedladdningar. Tilting Point är den nya generationens spelbolagspartner som förser ledande utvecklingsstudios med expertis, tjänster och operationell support för att optimera högkvalitativa livespel framgångsrikt. "Jag är mycket nöjd över det fortsatta partnerskapet med Tilting Point för den

Stillfront: Simutronics reclaims publishing services10.12.2018 14:11Pressmeddelande

PRESS RELEASE December 10, 2018 Simutronics reclaims the publishing services for SIEGE: Titan Wars globally except China Simutronics Corp, a studio within Stillfront Group AB, has ended a co-publishing agreement regarding the mobile game SIEGE: Titan Wars with New York based publishing partner Tilting Point. According to a new agreement, Tilting Point will continue to provide publishing services and market the game in China but Simutronics will run the publishing services and marketing globally from the Group going forward. Simutronics is a leading developer of online roleplaying and mobile games such as DragonRealms, GemStone IV and Lara Croft Relic Run, the latter with more than 23 million downloads. Tilting Point is a new-generation games partner that provides top development studios with expert resources, services, and operational support to optimize high quality live games for success. "I am very pleased to continue the partnership with Tilting Point for the Chinese market as this

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

Corline Biomedical AB: Patientrekrytering startar i Renaparin-studie30.11.2018 16:37Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att patientrekrytering i den kliniska fas 1-studien RENAPAIR-01 startar. I studien utvärderas bolagets läkemedelskandidat Renaparin® som är under utveckling för att förbättra utfallet av njurtransplantation. Patienter kommer inledningsvis att rekryteras på Akademiska sjukhuset i Uppsala. När de fyra första patienterna utvärderats inleds också rekrytering på Karolinska Universitetssjukhuset i Huddinge. Beskedet att patientrekrytering startar innebär att förberedelsearbetet inför studiestart är avslutat och att till exempel avtal, initieringsmöte, logistik, provhantering och monitorering är hanterat, samt att godkänt prövningsläkemedel nu finns tillgängligt för rekvirering av kirurgerna på transplantationskliniken i Uppsala för dosering till donatornjurar. När första patient doserats kommer detta meddelas separat. Corline har utvecklat och äger rättigheterna till Renaparin® som administreras direkt till den donerade njuren i

Stillfront: Bytro Labs lanserar en ny version av Supremacy 191427.11.2018 08:00Pressmeddelande

PRESSMEDDELANDE 2018-11-27 Bytro Labs, en studio inom Stillfront Group, lanserar en ny version av Supremacy 1914 Spelutvecklaren Bytro Labs, mest kända för sitt framgångsrika strategispel Call of War, har släppt en ny version av sin klassiska speltitel Supremacy 1914. Dagens lansering är den första av tre milstolpar för den nya versionen av Supremacy 1914 - The Great War som släpps 2019. Den första uppdateringen innehåller en komplett omarbetning av området för spelets community, ett nytt utseende för kartan samt ny 3D-teknologi. I nästa steg kommer Bytro Labs att gå vidare till "true cross platform" där spelet tillgängliggörs för fler plattformar, en strategi som tidigare har varit framgångsrik för titeln Call of War. Supremacy 1914 - The Great War släpps för Android senare i år och i början av 2019 släpps spelet för iOS och Steam. Det tredje och sista steget i lanseringen kommer i mitten av 2019 innehållande en större uppdatering avseende både innehåll och funktion, som färdigställer

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum